TG Therapeutics | TGTX - Sales Revenues


TG Therapeutics reported $259.94M in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
Alaunos Therapeutics USD 2K 2K Mar/2025
Amgen USD 10.4B 300M Sep/2026
Ardelyx USD 120.88M 26.41M Jun/2026
Arrowhead Research USD 75.23M 1.49M Jun/2026
Bayer EUR 10.05B 820M Sep/2026
Biogen USD 2.8B 60M Sep/2026
Corcept Therapeutics USD 340.5M 84.35M Sep/2026
Curis USD 1.14M 1.41M Dec/2025
Gilead Sciences USD 8.3B 500M Sep/2026
J&J USD 25.4B 89M Sep/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Novartis USD 14.52B 112M Sep/2026
Novavax USD 147.14M 76.69M Dec/2025
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
TG Therapeutics USD 259.94M 19.6M Sep/2026
Verastem USD 18.67M 1.14M Mar/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026